Other targeted drugs in melanoma
Citations
89 citations
Cites background from "Other targeted drugs in melanoma"
...Unfortunately, no clinical responses to lapatinib were observed in a Phase II trial in HER4-mutant patients [136]....
[...]
80 citations
Cites background from "Other targeted drugs in melanoma"
...ERK provides another downstream point of inhibition, and ERK inhibition may also reduce the chance for developing feedback resistance (49, 50)....
[...]
63 citations
Cites background from "Other targeted drugs in melanoma"
...Finally, dabrafenib and trametinib showed to significantly improve patients’ quality of life compared to both dabrafenib and vemurafenib monotherapy (Grob et al., 2015; Schadendorf et al., 2015), while vemurafenib and cobimetinib showed to maintain the patient’s quality of life compared with…...
[...]
22 citations
17 citations
References
9,785 citations
"Other targeted drugs in melanoma" refers background in this paper
...Recently the identification of the BRAF mutation in 50% of melanomas has led to development of the first targeted drugs for this disease (4)....
[...]
2,144 citations
"Other targeted drugs in melanoma" refers background in this paper
...The combination of BRAF and MEK inhibitors has demonstrated an even higher activity in BRAF mutant melanomas with response rates close to 80% and a significant improvement in median survival (close to 2 years) (5-7)....
[...]
1,715 citations
"Other targeted drugs in melanoma" refers background in this paper
...The combination of BRAF and MEK inhibitors has demonstrated an even higher activity in BRAF mutant melanomas with response rates close to 80% and a significant improvement in median survival (close to 2 years) (5-7)....
[...]
1,341 citations
"Other targeted drugs in melanoma" refers background in this paper
...Overexpression of Hsp90 in tumors has been associated with drug resistance and poor prognosis (112)....
[...]
1,321 citations
"Other targeted drugs in melanoma" refers background in this paper
...The most frequent mechanisms of resistance to BRAF inhibitors are the acquisition of a new NRAS mutation, overexpression of COT, or new splicing forms of BRAF (9-11)....
[...]